KRAS and adenocarcinoma: KRAS c12/13 mutations in serrated adenocarcinomas were never accompanied by MSI-H, in contrast to 15/27 (55.6%) of MSS/MSI-L cases harbouring a KRAS mutation (P = 0.075).